Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 09:56 am IST
Share
Samil Pharmaceutical Co.,Ltd reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 587.85 million compared to KRW 526 million a year ago. Net loss was KRW 274.1 million compared to KRW 1,153.28 million a year ago. Basic loss per share from continuing operations was KRW 20 compared to KRW 83.6364 a year ago. Diluted loss per share from continuing operations was KRW 20 compared to KRW 83.6364 a year ago. Basic loss per share was KRW 20 compared to KRW 83.6364 a year ago.
For the six months, sales was KRW 1,890.22 million compared to KRW 927.52 million a year ago. Net income was KRW 61.7 million compared to net loss of KRW 544.84 million a year ago. Basic earnings per share from continuing operations was KRW 4.5455 compared to basic loss per share from continuing operations of KRW 40 a year ago. Diluted earnings per share from continuing operations was KRW 3.6364 compared to diluted loss per share from continuing operations of KRW 40 a year ago. Basic earnings per share was KRW 4.5455 compared to basic loss per share of KRW 40 a year ago. Diluted earnings per share was KRW 3.6364.
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Companyâs products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
SAMIL PHARMACEUTICAL CO.,LTD 
